Targeting Lipoprotein(a) to reduce residual risk in high risk atherosclerotic cardiovascular disease patients

Authors

  • Ashley A Waring Cardiology, Medical University of South Carolina, USA.
  • Pamela B Morris Cardiology, Medical University of South Carolina, USA

Keywords:

Lipoprotein(a), Residual risk, Secondary prevention, Antisense oligonucleotide, Small-interfering RNA

Abstract

Abnormal lipoprotein(a) [Lp(a)] levels are associated with an elevated risk of cardiovascular events. Lp(a) has been used to risk stratify primary prevention patients, and more recently, it has been identified as a marker of residual risk in secondary prevention patients. Treatment for these patients is limited to LDL lowering therapies and optimizing lifestyle changes. Novel nucleic acid therapies that target Lp(a) production, including antisense oligonucleotide (pelacarsen) and small-interfering RNA (olpasiran), are safe and markedly lower Lp(a) levels. Phase 3 trials, HORIZON and OCEAN(a), are currently studying if significant reduction in Lp(a)
with these drugs will lower major adverse cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD).

Downloads

Published

2023-06-29

Issue

Vol. 52 No. 2 (2023): Journal of the Argentinian Federation of Cardiology

Section

Review Article

How to Cite

1.
Targeting Lipoprotein(a) to reduce residual risk in high risk atherosclerotic cardiovascular disease patients. Rev. Fed. Arg. Cardiol. [Internet]. 2023 Jun. 29 [cited 2024 Jul. 3];52(2):59-64. Available from: https://revistafac.org.ar/ojs/index.php/revistafac/article/view/499